Statistical parametric mapping reveals regional alterations in cannabinoid CB1 receptor distribution and G-protein activation in the 3D reconstructed epileptic rat brain

Epilepsia. 2012 May;53(5):897-907. doi: 10.1111/j.1528-1167.2012.03460.x. Epub 2012 Apr 17.

Abstract

Purpose: The endocannabinoid system is known to modulate seizure activity in several in vivo and in vitro models, and CB(1) -receptor activation is anticonvulsant in the rat pilocarpine model of acquired epilepsy (AE). In these epileptic rats, a unique redistribution of the CB(1) receptor occurs within the hippocampus; however, an anatomically inclusive analysis of the effect of status epilepticus (SE)-induced AE on CB(1) receptors has not been thoroughly evaluated. Therefore, statistical parametric mapping (SPM), a whole-brain unbiased approach, was used to study the long-term effect of pilocarpine-induced SE on CB(1) -receptor binding and G-protein activation in rats with AE.

Methods: Serial coronal sections from control and epileptic rats were cut at equal intervals throughout the neuraxis and processed for [(3) H]WIN55,212-2 (WIN) autoradiography, WIN-stimulated [(35) S]GTPγS autoradiography, and CB(1) -receptor immunohistochemistry (IHC). The autoradiographic techniques were evaluated with both region of interest (ROI) and SPM analyses.

Key findings: In rats with AE, regionally specific increases in CB(1) -receptor binding and activity were detected in cortex, discrete thalamic nuclei, and other regions including caudate-putamen and septum, and confirmed by IHC. However, CB(1) receptors were unaltered in several brain regions, including substantia nigra and cerebellum, and did not exhibit regional decreases in rats with AE.

Significance: This study provides the first comprehensive evaluation of the regional distribution of changes in CB(1) -receptor expression, binding, and G-protein activation in the rat pilocarpine model of AE. These regions may ultimately serve as targets for cannabinomimetic compounds or manipulation of the endocannabinoid system in epileptic brain.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Anticonvulsants / pharmacology
  • Anticonvulsants / therapeutic use
  • Benzoxazines / pharmacokinetics
  • Brain / drug effects
  • Brain / metabolism*
  • Brain / pathology*
  • Brain Mapping
  • Diazepam / pharmacology
  • Diazepam / therapeutic use
  • Disease Models, Animal
  • Epilepsy / chemically induced
  • Epilepsy / drug therapy
  • Epilepsy / pathology*
  • GTP-Binding Proteins / metabolism*
  • Gene Expression Regulation / drug effects
  • Guanosine 5'-O-(3-Thiotriphosphate) / pharmacokinetics
  • Imaging, Three-Dimensional*
  • Male
  • Morpholines / pharmacokinetics
  • Naphthalenes / pharmacokinetics
  • Pilocarpine / toxicity
  • Radioligand Assay
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Cannabinoid, CB1 / metabolism*
  • Sulfur Isotopes / pharmacokinetics
  • Time Factors
  • Tritium / pharmacokinetics

Substances

  • Anticonvulsants
  • Benzoxazines
  • Morpholines
  • Naphthalenes
  • Receptor, Cannabinoid, CB1
  • Sulfur Isotopes
  • Pilocarpine
  • Tritium
  • Guanosine 5'-O-(3-Thiotriphosphate)
  • (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone
  • GTP-Binding Proteins
  • Diazepam